 |
The next-generation skin analysis platform, set to redefine the aesthetic consultation experience
CAESAREA, Israel, May 27, 2025 /PRNewswire/ -- Alma, a Sisram Medical company and a global leader in energy-based medical and aesthetic solutions, has officially launched Alma IQ, its next-generation imaging platform, at the eighth Alma Academy, held in Dubrovnik, Croatia. The event gathered nearly 400 physicians and partners from over 46 countries, marking one of Alma's largest global educational event to date.
Introduced to a global audience through exclusive live demonstrations, Alma IQ, redefines how practitioners and patients approach aesthetic care from the very first consultation. By delivering real-time, high-definition insights beneath the skin's surface, the platform reveals what the eye cannot see, empowering aesthetic professionals to make informed decisions with unprecedented precision.
At the core of Alma IQ is a powerful multi-modal imaging system developed in collaboration with Sylton, a global leader in aesthetic skin visualization. In under 10 seconds, it captures high-resolution images using specialized light modes: True UV, Cross Polarized, Parallel Polarized, and proprietary 360° Light Technology. These reveal skin aspects from texture and pigmentation to inflammation and vascularity, providing a comprehensive profile that helps clinics communicate treatments clearly and foster more informed, engaged patient experiences.
"Advanced personalization starts with clarity," said Lior Dayan, CEO of Alma and Sisram Medical. "In aesthetics, the ability to truly see what lies beneath the surface is everything—it's the power to see what others can't, and to treat what others don't."
He continued: "Alma IQ delivers that clarity in a way that's both immediate and deeply personal. This is more than technology. It's a shift in how we connect and communicate with patients. It transforms the consultation into a moment of insight and trust—establishing a new foundation for intelligent, personalized aesthetic care."
Recognized as the industry's leading global education forum, this year's summit, held from May 22-25, featured 19 internationally renowned experts, including Prof. Ofir Artzi (Israel), Dr. Pina Panchal (U.S.), Dr. Fatima Aguero (Paraguay), and Dr. Chytra Anand (India). In alignment with this year's theme, "The Art of the Patient," each shared advanced clinical strategies and uncovered patient perspectives that put personalization at the forefront of the practice. Among the topics covered were skin aging, pigmentation, scarring, skin tightening, and rejuvenation.
The event also featured live demonstrations of Alma's award-winning portfolio of technologies including Alma Harmony, the multi-application platform renowned for its versatility in aesthetic and skin rejuvenation treatments, alongside Harmony Bio-Boost, the brand's signature facial designed to deliver plump, glowing skin with no downtime.
Attendees also experienced the global debut of Alma IQ, Alma Hybrid, renowned for its precision in treating scars as well as Alma PrimeX and Opus, both offering advanced, non-invasive solutions for skin tightening, resurfacing, and full-body rejuvenation.
About Alma Academy
Recognized as the leading professional academy event in the aesthetic industry, Alma Academy is designed to shape the next era of aesthetic medicine through clinical mastery, innovation, and global collaboration. Held annually in key international hubs, including Greece, Spain, Dubai, North America, Italy, and Thailand, the Academy brings together the world's foremost practitioners for a dynamic platform of hands-on training, real-world protocols, and expert-led dialogue.
Learn more https://almalasers.com/alma-academy/#
About Alma
Alma is a global leader in medical aesthetic solutions, with over 25 years of innovation. We empower practitioners to deliver safe, effective, and life-transforming treatments to their patients, utilizing state-of-the-art, clinically proven solutions such as energy-based device lasers, diagnostics, injectables, and advanced skincare. Alma's multiple award-winning products have set a new benchmark in the medical aesthetic industry, both in terms of clinical excellence and groundbreaking innovations.
Visit https://almalasers.com/
Video - https://www.youtube.com/watch?v=5UJZLr9pWnM
Media Inquiries:
prglobal@almalasers.com
The next-generation skin analysis platform, set to redefine the aesthetic consultation experience
CAESAREA, Israel, May 27, 2025 /PRNewswire/ -- Alma, a Sisram Medical company and a global leader in energy-based medical and aesthetic solutions, has officially launched Alma IQ, its next-generation imaging platform, at the eighth Alma Academy, held in Dubrovnik, Croatia. The event gathered nearly 400 physicians and partners from over 46 countries, marking one of Alma's largest global educational event to date.
Introduced to a global audience through exclusive live demonstrations, Alma IQ, redefines how practitioners and patients approach aesthetic care from the very first consultation. By delivering real-time, high-definition insights beneath the skin's surface, the platform reveals what the eye cannot see, empowering aesthetic professionals to make informed decisions with unprecedented precision.
At the core of Alma IQ is a powerful multi-modal imaging system developed in collaboration with Sylton, a global leader in aesthetic skin visualization. In under 10 seconds, it captures high-resolution images using specialized light modes: True UV, Cross Polarized, Parallel Polarized, and proprietary 360° Light Technology. These reveal skin aspects from texture and pigmentation to inflammation and vascularity, providing a comprehensive profile that helps clinics communicate treatments clearly and foster more informed, engaged patient experiences.
"Advanced personalization starts with clarity," said Lior Dayan, CEO of Alma and Sisram Medical. "In aesthetics, the ability to truly see what lies beneath the surface is everything—it's the power to see what others can't, and to treat what others don't."
He continued: "Alma IQ delivers that clarity in a way that's both immediate and deeply personal. This is more than technology. It's a shift in how we connect and communicate with patients. It transforms the consultation into a moment of insight and trust—establishing a new foundation for intelligent, personalized aesthetic care."
Recognized as the industry's leading global education forum, this year's summit, held from May 22-25, featured 19 internationally renowned experts, including Prof. Ofir Artzi (Israel), Dr. Pina Panchal (U.S.), Dr. Fatima Aguero (Paraguay), and Dr. Chytra Anand (India). In alignment with this year's theme, "The Art of the Patient," each shared advanced clinical strategies and uncovered patient perspectives that put personalization at the forefront of the practice. Among the topics covered were skin aging, pigmentation, scarring, skin tightening, and rejuvenation.
The event also featured live demonstrations of Alma's award-winning portfolio of technologies including Alma Harmony, the multi-application platform renowned for its versatility in aesthetic and skin rejuvenation treatments, alongside Harmony Bio-Boost, the brand's signature facial designed to deliver plump, glowing skin with no downtime.
Attendees also experienced the global debut of Alma IQ, Alma Hybrid, renowned for its precision in treating scars as well as Alma PrimeX and Opus, both offering advanced, non-invasive solutions for skin tightening, resurfacing, and full-body rejuvenation.
About Alma Academy
Recognized as the leading professional academy event in the aesthetic industry, Alma Academy is designed to shape the next era of aesthetic medicine through clinical mastery, innovation, and global collaboration. Held annually in key international hubs, including Greece, Spain, Dubai, North America, Italy, and Thailand, the Academy brings together the world's foremost practitioners for a dynamic platform of hands-on training, real-world protocols, and expert-led dialogue.
Learn more https://almalasers.com/alma-academy/#
About Alma
Alma is a global leader in medical aesthetic solutions, with over 25 years of innovation. We empower practitioners to deliver safe, effective, and life-transforming treatments to their patients, utilizing state-of-the-art, clinically proven solutions such as energy-based device lasers, diagnostics, injectables, and advanced skincare. Alma's multiple award-winning products have set a new benchmark in the medical aesthetic industry, both in terms of clinical excellence and groundbreaking innovations.
Visit https://almalasers.com/
Video - https://www.youtube.com/watch?v=5UJZLr9pWnM
Media Inquiries:
prglobal@almalasers.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alma Unveils Alma IQ at Eighth Global Alma Academy in Dubrovnik
Alma Unveils Alma IQ at Eighth Global Alma Academy in Dubrovnik
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
